---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098404"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:10:40.401529+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations

## Summary
- Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.
- Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.
- Company expects to pursue sale or monetization of remaining assets and orderly wind down of operations.
- Warns that it is unlikely there will be meaningful cash available for distribution to stockholders.
- May file Form 15 to suspend SEC reporting obligations after delisting.

## SEC filing metadata
- accession: 0001104659-25-098404
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/tm2528458d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098404
- JSON: https://secwatch.observer/filing/0001104659-25-098404.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098404.txt

## Source-grounded claims
- claim_id: e4d9522e41d7543182a0261874dfae5fc41caacf
  claim: Carisma Therapeutics Inc. received a nasdaq delisting notice notice regarding other.
  evidence_excerpt: October 9, 2025, Carisma Therapeutics Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities and Exchange Commissio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.